Allele loss from 5q21 (APC/MCC) and 18q21 (DCC) and DCC mRNA expression in breast cancer. by Thompson, A. M. et al.
Br. J. Cancer (1993), 68, 64-68 1993
Allele loss from 5q21 (APC/MCC) and 18q21 (DCC) and DCC mRNA
expression in breast cancer
A.M. Thompson', R.G. Morris2, M. Wallace3, A.H. Wyllie2, C.M. Steel3 & D.C. Carter'
'University Department ofSurgery, The Royal Infirmary, Lauriston Place, Edinburgh; 2Cancer Research Campaign Laboratories
Department ofPathology, University ofEdinburgh, Teviot Place, Edinburgh; 3MRC Human Genetics Unit, Western General
Hospital, Crewe Road, Edinburgh, UK.
Summary Thirty-four primary, untreated sporadic breast cancers were examined for loss of heterozygosity
(LOH) at tumour suppressor loci involved in colorectal cancer: APC/MCC at 5q21 and DCC at 18q21. LOH
was identified in 28% informative patients at 5q21 and 31% at 18q21. LOH at 5q21 and 18q21 was compared
with allele loss at 17p13 and concurrent LOH at two or more of the loci was noted in 24% of tumours.
Expression of a 12 kb DCC mRNA was demonstrated in 14/34 (42%) of the cancers and in all five tumours
with LOH at the DCC locus there was an additional 11 kb DCC mRNA. Abnormalities of three loci involved
in colorectal cancer (5q21, 17pl3 and 18q21) therefore also occur in sporadic breast cancer. The accumulation
of such genetic abnormalities may confer a growth advantage important in the development of breast
cancer.
Loss of heterozygosity (LOH or allele loss) has become
established as a marker for tumour suppressor gene loss at
several loci in a wide range of cancers. Certain sites,
identified by LOH studies, may contain tumour suppressor
genes involved in more than one type of malignancy. The
paradigm for this is the p53 tumour suppressor gene for
which LOH, often with mutation of the remaining allele, has
been described in many types of cancer. While the p53 gene
has been extensively investigated, other loci involved in col-
orectal cancer such as 5q21, which contains the adenomatous
polyposis coli (APC) and mutated in colon cancer (MCC)
genes, and 18q21.3 bearing the deleted in colon cancer
(DCC) locus have been less well documented in other cancer
types.
5q21 (APC/MCC)
There is strong evidence for the involvement of the 5q21
locus in colorectal cancer. Loss of heterozygosity from 5q21
has been identified in over 40% of sporadic colorectal
cancers (Solomon et al., 1987; Vogelstein et al., 1988;
Ashton-Rickart et al., 1989; Fearon & Vogelstein, 1990) and
may be an early event in colorectal neoplasia since 5q21
LOH has been demonstrated in small colonic adenomas
(Vogelstein et al., 1988). Furthermore, somatic mutations
have been identified within the APC and MCC genes in
colorectal cancers (Nishisho et al., 1991; Kinzler et al.,
1991a).
LOH from 5q21 has also been noted in 21-40% of non
small cell lung cancers (Ashton-Rickart et al., 1991; D'Amico
et al., 1992), 80% of small cell lung cancers (D'Amico et al.,
1992) and 77% of oesophageal cancers (Boynton et al.,
1992).
The function and interaction of MCC and APC remains
speculative, but two functions, as a G protein and 'coiled
coil', have attracted debate. The MCC gene, and to a lesser
extent the APC gene, shares a short region of similarity with
the m3 muscarinic acetylcholine receptor which mediates
acetylcholine stimulation of phosphoinositide-specific phos-
pholipase C via a G protein (Kinzler et al., 1991a; Bourne,
1991). It is therefore possible that both APC & MCC prod-
ucts may operate on the same biochemical pathway (Nish-
isho et al., 1991). Analysis of the MCC and APC sequence
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reveal regions with strong coiled coil potential (Bourne, 1991)
similar to nuclear lamin and intermediate filament proteins
(Kinzler et al., 1991b). These gene products often undergo
homo and hetero-oligomerisation and this has led to specula-
tion that APC and MCC may interact. Disruption of these
macromolecular structures may lead to a functional deficit,
with de-repression of a mitogenic signal setting the stage for
tumour progression by subsequent deletion of other normal
genes (Bourne, 1991; Groden et al., 1991; Joslyn et al., 1991).
Whatever the function(s) of MCC and APC, mutations in
either gene usually result in stop codons or affect splice site
consensus elements (Nishisho et al., 1991) and in lung
cancers LOH of both APC and MCC may occur (D'Amico
et al., 1992).
DCC (18q21.3)
The predicted amino acid sequence of DCC specifies a
190 kD transmembrane phosphoprotein with 42% homology
to neural cell adhesion molecules (N-CAM), a fibronectin
type III related domain and four immunoglobulin domains
of the C2 class (Fearon et al., 1990). Thus, loss of DCC
function may confer a growth advantage on evolving tumour
cells (Weinberg, 1991).
LOH at the DCC locus (18q21.3), has been demonstrated
in 71% ofsporadic colorectal cancers (Vogelstein et al., 1988;
Fearon et al., 1990). Indeed, LOH from 18q may be a
particular feature of gastrointestinal cancers: gastric cancer
shows 61% LOH at the DCC locus (Uchino et al., 1992) and
pancreatic cancers and pancreatic cell lines show loss ofDCC
expression (Hohne et al., 1992). However, LOH from 18q
has now been reported in up to 64% of osteosarcomas
(Yamaguchi et al., 1992), 60% of ovarian cancers (Chenevix-
Trench et al., 1992), 33% of renal tumours (Bergerheim et
al., 1989) and 11% of lung cancers (Yokota et al., 1987). In
sporadic breast cancer, reports of LOH at the DCC locus
range from only I of 40 (2.5%) informative cancers (Sato et
al., 1991) to 13/45 (27%) tumours with DCC allele loss or
duplication (Devilee et al., 1991). Less specific markers (OS4
at 18q21.3-qter) have shown 69% (11/34) allele loss (Cropp
et al., 1990), 14% allele loss (Merlo et al., 1992), or 38%
(17/45) allelic imbalance (Devilee et al., 1991) in breast
cancer.
The aims of this work were:
(1) to determine whether LOH occurs at 3 loci involved in
colorectal cancer: 5q21 (APC/MCC), 18q21 (DCC) and
17pl3 (pS3) in a series of sporadic breast cancers and
(2) to identify whether DCC gene mRNA is expressed in
breast cancer.
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Materials and methods
Tissues
Tumour tissue was snap frozen in liquid nitrogen at the time
of surgical resection from 34 patients with primary, untreated
breast cancer. Adjacent tissue was fixed for histopathology
and submitted for oestrogen receptor assay. From each
patient, 20 ml venous blood was withdrawn pre-operatively
for constitutional DNA extraction from venous blood lym-
phocytes. For the RNA studies, normal (reduction mammo-
plasty) breast tissue, tonsil tissue and normal colonic mucosa
(negative controls), normal brain (positive control), the
breast cancer cell line MCF 7 T47D and MDAMB231 grown
in vitro and MCF 7 xenograft tumour material (Thompson et
al., 1990a) were also snap frozen and stored at - 70°C.
Nucleic acid extraction
High molecular weight DNA was extracted from paired
frozen tumour tissue and venous blood lymphocytes. Briefly,
the tissues or cells were lysed with SDS, protein digested and
removed by phenol/chloroform extraction then DNA precipi-
tated using ethanol in the presence of salt. The DNA was
redissolved in Tris/EDTA buffer and the concentration and
purity determined by spectrophotometry at 260 nm and
280 nm (Thompson et al., 1990b).
Total RNA was extracted using a modification of the
lithium chloride/urea differential precipitation method
(Thompson et al., 1990b), which utilises ultrasonic disruption
of DNA, then proteinase K treatment and phenol extraction
to remove protein, followed by precipitation of the total
RNA using alcohol. The RNA was redissolved in double
autoclaved diethyl pyrocarbonate (DEPC) treated water, the
quantity and purity of the RNA determined by spectro-
photometry at 260 nm and 240 nm and the RNA stored in
aliquots at - 70°C.
Southern blot analyses
DNA (5 rg) from each patient's blood and tumour was
digested using an appropriate bacterial endonuclease, the
pairs of blood (constitutional) and tumour DNA subjected to
electrophoresis alongside digested lamda markers on a 0.8%
agarose gel, the DNA fragments transferred by Southern
blotting to hybond-N membrane (Amersham, UK) and fixed
to the membrane by exposure to ultraviolet light.
The hybond nylon membrane was pre-hybridised in hybri-
disation buffer (5 x Denharts, 5 x SSC, 0.1% SDS, 10% dex-
tran sulphate). To this 107cpm ml-' 32p CTP probe, labelled
using a random-prime DNA-labelling system (Boehringer
Mannheim), was added and allowed to hybridise for 24 h.
Excess probe was washed off the membrane using successive
washes of 0.1% SDS and 1 x SSC and the DNA alleles
detected by auto-radiography with Kodak XAR film at
- 70°C.
The probes used to examine the blood/tumour pairs (Table
I) included five probes for 5q21, three probes for I7p13 and
four probes for 18q21.
Northern blot analyses
Total RNA (20 fg from each sample) was denatured, loaded
with ethidium bromide on a denaturing 1.1% agarose gel and
the RNA species separated by electrophoresis. The gel was
washed in standard saline citrate then the RNA transferred
by electroblotting (to ensure transfer of large mRNA species)
to hybond-N membrane, and the RNA covalently fixed to
the membrane using an ultraviolet transilluminator and,
together with the gel, photographed to demonstrate complete
transfer of the RNA.
To detect gene expression, the nylon filter was prehyb-
ridised in 7% SDS, 0.5 m disodium hydrogen phosphate
(pH 7.2) and 1 mM EDTA pH 7.0 (after Church & Gilbert,
1984) for 30 min at 65°C, 32P-CTP labelled probe DCC 1.65
Table I
Probe Location Reference
pi227 5q 21 Dunlop et al. (1990)
L562.2 5q 21 Dunlop et al. (1990)
L571.3 5q 21 Nakamura et al. (1990)
EF5.44 5q 21 Nakamura et al. (1990)
YN5.48 5q 21 Dunlop et al. (1990)
pBHp53 17pl3.1 Hoyheim et al. (1989)
MCT35.1 17pl3.1 Nakamura et al. (1988)
YNZ22 17pl3.1 Nakamura et al. (1988)
p15.65 18q21.3 Fearon et al. (1990)
Saml.1 18q21 Peltomaki et al. (1991)
DCCI.0 DNA for nucleotides Fearon et al. (1990)
1760 to 2205 of DCC.
DCC1.65 DNA for nucleotides 591 Fearon et at. (1990)
to 2250 of DCC.
(specific activity I07 cpm ml-', labelled as above) added and
hybridised at 65°C. Excess probe was washed off stringently
using 0.1% SDS x 10 mM disodium hydrogen phosphate at
65°C and the DCC messenger RNA detected by autoradio-
graphy using Kodak XAR film at - 70C for up to 14 days.
Filters were stripped of DCC 1.65 and reprobed for alpha
actin mRNA (Minty et al., 1981) under the same conditions
as an internal control for loading.
Results
DNA studies
DNA was extracted from the 34 patients and probed to
detect allele losses at three colorectal loci - the APC/MCC,
p53 and DCC loci (Table II). Using five probes mapping to
5q21 (Table I), 25 of the 32 patients examined were infor-
mative for at least one probe and seven (28%) exhibited
unequivocal allele loss (Figure 1). At 18q21, 15 of the 26
patients were informative using the p15.65 and Saml.1
probes and 5 (31%) showed allele loss (Figure 2). At I7pI3,
31 of the 34 patients were informative and 22 (71%) had loss
of heterozygosity. A more detailed comparison of the three
regions (Figure 3) shows that all 34 patients were informative
at one or more of the three loci examined and ten patients
were informative for all three regions. Twenty-four out of 34
(71%) tumours exhibited loss of heterozygosity from at least
one locus. One tumour had allele losses at all three tumour
suppressor loci (5q + 17p + 18q), five tumours had allele
losses from 5q + 17p and three tumours from 17p + 18q.
However 15 of the 34 informative tumours (47%) had loss of
heterozygosity at only one locus (17p-thirteen; Sq-one; 18q-
one). No DNA rearrangements were identified at any of the
three loci examined.
Four of the 34 cancers had p53 mutations in exons 5-9
identified using the HOT technique and confirmed by direct
DNA sequencing (Thompson et al., 1992), but the mutations
were not clearly associated with detectable alterations at the
APC/MCC or DCC loci.
RNA studies
Using probe DCC 1.65, mRNA species were detected in
extracts from 14 of the 34 breast cancers, the brain and the
MCF-7 xenograft but not in the MCF7, T47D or MDAM-
B231 cell cultures, normal breast, normal colonic or normal
Table II
No. patients No. patients Tumours with
Chromosome examined informative allele loss (%)
5q21 32 25 7 (28%)
17pl3 34 31 22 (71%)
18q21 26 16 5 (31%)66 A.M. THOMPSON etal.
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Figure 1 Southern blot of breast tumours probed at 5q21.
Paired blood/tumour DNA probed with YN5.48 following
enzyme digestion of the DNA with Msp 1. Blood/tumour pairs
show no allele loss (left pair) or loss of an allele (right pair) in the
tumour compared with the constitutional (blood lymphocyte)
DNA.
Msp I pBV 15.65.
B T B T B T B T
Figure 2 Allele loss from DCC in breast cancer. Four blood/
tumour pairs digested with Msp 1 and probed at the DCC locus
on 18q21 with p15.65 demonstrating unequivocal allele loss (loss
ofheterozygosity) from the tumour DNA in the second and third
B/T pairs, but no allele loss from the outer two B/T pairs.
lymphoid (tonsil) tissue samples (Figure 4). In all five
tumours with loss of heterozygosity at the DCC locus, two
mRNA species for DCC of 12 kb + 11 kb were identified
(Table III and Figure 4). In the remaining nine breast
tumours exhibiting DCC mRNA expression five were heter-
ozygous with retention of both alleles in the tumour and four
were not informative.
Patient No. 5q21-22 17p13 18q21
4 00 0
16 ?
53 0 0
85 0
75 0
86 Q
39 0 0 S
45 0 0 0
87 0
8 0 0
21 0 ?
22 0 * 0
29 ?
36 *
51 0 *
69 * ?
74 0 0 0
77 0 * 0
79 0 ?
80 * 0
90 Q
92 *
48
54 0 0 0
15 0 0
23 ?
26 Q ?
28 0 0
35 0 0 0
46 ?
72 0 .0 0
73 ?
88 0 e
91 ?
* Loss of heterozygosity (allele loss)
O Not informative (constitutional DNA not heterozygous)
0 Heterozygosity retained (no allele loss)
? No information available
Figure 3 Results of Southern blots in 34 breast cancers at 5q21,
17pl3 and 18q21.
Clinical associations
There were no associations between allele losses at 5q21 or
18q21 and the oestrogen receptor content of the tumour,
tumour size or stage or histological features. For l7pl3, 15
of the 22 tumours with allele loss were oestrogen receptor
poor (less than 20 fmol mgprotein-') but only three of nine
tumours with retention of heterozygosity were oestrogen
receptor poor. Four of the five tumours which expressed the
truncated DCC mRNA of 11 kb were oestrogen receptor
moderate or rich (greater than 20 fmol mg protein-').
Discussion
This study examined 34 untreated sporadic primary breast
cancers for LOH at 5q21 and 18q21, and compared these
events to LOH and mutation of the p53 gene. We have
identified tumour allele losses at 5q21 (APC/MCC) in 28% of
informative patients and at 18q21 (DCC) in 31% of patients
compared with 71% LOH at 17pl3 (p53).
Clearly LOH at 5q21 (APC/MCC) occurs in sporadic
breast cancers as in other types of malignancy (Solomon et
al., 1987; Vogelstein et al., 1988; Ashton-Rickart et al., 1989;
Fearon & Vogelstein, 1990; Miki et al., 1991), at a similar
rate to non small cell lung cancer (Ashton-Rickart et al.,
1991). Detailed studies of 5q21 in sporadic colorectal cancer
suggest that APC or MCC can be the targets for deletion,
although either may be involved in individual tumours
(Nishisho et al., 1991; Kinzler et al., 1991b). Detailed studies
of 5q21 in breast cancer (including mutation analysis) would
be required before there was conclusive evidence of APC or
MCC involvement: there are other candidate genes within the
region - Ter (a tyrosine kinase homologue to src), TBI
(which has similarities to ADP/ATP carrier/translocation
genes) SRP19 and TB2 (Kinzler et al., 1991b; D'Amico et al.,
1992).
At the DCC locus, we have identified LOH in five cancers
from 16 informative patients (31%) using two intragenic
polymorphic markers (p15.65 and Saml.l) confirming the
earlier report that 29% of cancers have allelic imbalance atAPC/MCC AND DCC IN BREAST CANCER 67
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Figure 4 mRNA expression detected with DCC 1.65. DCC
mRNA expression of a 12 kb DCC mRNA (in lanes 1, 2, 3 and
31) and 12 kb + 1 kb DCC mRNA (in lanes 6+7) detected on
Northern blot autoradiographs probed sequentially with DCC
1.65 for nucleotides 591 to 2250 of the DCC gene (96 h exposure;
upper set) and aipha-actin as the 1.8 kb internal control mRNA
for loading (24 h exposure; lower set). Lane 1 brain; lane 2
tumour 88, lane 3 tumour 23, lane 4 tumour 35 (all with retained
heterozygosity at 18q23); lane 5 normal breast; lane 6 tumour 4,
lane 7 tumour 39, (both with LOH at 18q); lane 8 MDAMB 231
cell line, lane 9 T47D cell line, lane 10 MCF7 cell line, lane 11
MCF7 xenograft.
Table III
Patient DCC allele status DCC mRNA expression
4 LOH 12kb+11kb
39 LOH 12 kb + 11 kb
45 LOH 12 kb + 11 kb
54 LOH 12kb+ 11 kb
87 LOH 12 kb + II kb
88 Ret 12 kb
35 Ret nil
74 NI nil
22 NI 12 kb
Key: LOH = loss of heteroxygosity; NI = not informative;
Ret = heterozygosity retained; 12 kb = size of mRNA transcript in
kilobases.
the DCC locus (Devilee et al., 1991). As previously noted,
(Sato et al., 1991) there were no rearrangements of DCC in
the 34 breast cancers studied here; a rare event even in
colorectal cancer (Fearon et al., 1990). However, LOH from
18q21 in breast cancer appears to be less common than for
colorectal cancer (Vogelstein et al., 1988; Fearon et al., 1990),
gastric cancer (Uchino et al., 1992), ovarian cancer
(Chenevix-Trench et al., 1992) or osteosarcoma (Yamaguchi
et al., 1992).
We present the first evidence for DCC gene mRNA expres-
sion in human breast cancer. As expected, brain tissue ex-
pressed DCC mRNA, but we were unable to demonstrate
DCC mRNA expression in three breast cancer cell lines, as
for most colorectal cancer cell lines (Fearon et al., 1990), or
in normal breast tissue, lymphoid (tonsil) tissue or colonic
mucosa. While the absence of detectable DCC mRNA ex-
pression in some cancers may confer a growth advantage
(Weinberg, 1991), 14 cancers did express DCC mRNA and in
five there was an additional, truncated DCC mRNA. These
five tumours, which also had LOH at DCC, may contain
mutations that create a potential 3" splice acceptor site
(Fearon et al., 1990). Such mutations could result in abnor-
mal RNA processing to produce truly abnormal truncated
mRNA or simply alternatively spliced DCC mRNA. To date,
no protein product has been identified in these tumours
(Vogelstein, personal communication). Even in the presence
of abnormal DCC transcription, translation to protein may
be aberrant.
MCF-7 cells grown in vitro did not express detectable
DCC mRNA; grown as a tumour xenograft, high levels of
DCC mRNA were detected (Figure 4). It is possible that
DCC expression may be increased in cells subjected to con-
tact inhibition in keeping with its suggested function as a cell
adhesion molecule (Fearon et al., 1990). However, at the
DNA and protein levels we have little idea of DCC function
or expression in these xenografts which grow slowly and
rarely metastasise (Thompson et al., 1990a). In addition,
other mechanisms such as enhancer mediated silencing or
gene methylation could account for DCC gene repression in
vitro (Hohne et al., 1992).
It has been suggested that there is a significant link in
breast cancer between LOH from 18q21 and LOH from
l7pl3 which bears the p53 locus (Cropp et al., 1990; Devilee
et al., 1991). We have previously documented p53 allele
losses and mutations (Thompson et al., 1992) in a series of
tumours which include those studied here at the DCC and
APC/MCC loci. As the detailed data shows (Figure 3), five
tumours had LOH from 5q concurrently with 17p LOH,
three tumours had LOH from both 18q and 17p and one
tumour had LOH from all three loci. Thus, concurrent allele
loss certainly occurs.
It is possible that the LOH observed in this study may be
due to chance. However, the accumulation of genetic defects
such as those demonstrated here, could confer a growth
advantage on a cell and allow subsequent clonal expansion
that makes further events at other crucial loci more likely
and may be important in the development of breast
cancer.
On the basis of the data presented here, we propose that
further study of the APC/MCC genes and DCC locus in
breast cancer, including structural analysis, merits considera-
tion.
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